【作者】 周昕；

【导师】 易铁钢；

【作者基本信息】 广州中医药大学 ， 中西医结合临床， 2010， 硕士

【摘要】 【目的】探讨健脾益肾丸对维持性血液透析(maintenance hemodialysis, MHD)患者微炎症状态的影响。【方法】随机选择20例本院MHD患者作为治疗组,进行自身前后对照,治疗期间予维持性血液透析的基础上加用健脾益肾丸,分别在治疗前、治疗后检测患者血清C反应蛋白(CRP)、白介素6(IL-6)和血浆内毒素水平,并进行比较。同时取20名健康成人作为正常对照组。【结果】1、治疗前患者血清CRP及血浆内毒素水平明显高于对照组(p<0.01),治疗后血清CRP及血浆内毒素水平较治疗前明显下降(p<0.05)。2、治疗前患者血清IL-6水平分别与对照组、治疗后比较均无明显差异(p>0.05)。3、治疗后临床症状累计得分数值较治疗前下降(p<0.05)。4、治疗前及治疗后患者血清K+均在正常范围之内,两组间比较无明显差异(p>0.05)。【结论】健脾益肾丸能有效降低MHD患者血清CRP及血浆内毒素水平,提示健脾益肾丸可以在一定程度上改善MHD患者微炎症状态。健脾益肾丸可有助于降低患者的临床症状积分,且不会升高血清K+水平。更多还原

【Abstract】 [Objectives] To investigate the effect of Kidney-benefiting and Spleen-fortifying Pill on microinflammatory state in patients with uremia undergoing maintenance hemodialysis.[Methods] Twenty patients with chronic renal failure during maintenance hemodialysis were randomly selected as the therapy group administrated with Kidney-benefiting and Spleen-fortifying Pill and twenty normal individuals were selected as the normal control group. The serum levels of C-reactive protein(CRP), interlukin-6 (IL-6) and the plasma level of endotoxin of each patient before and after treatment were measured respectively and compared with that of other patients and that of the normal control group.[Results] 1. Compared with the normal control group, the serum level of CRP and the plasma level of endotoxin were significantly higher in the therapy group (p<0.01). The serum level of CRP and the plasma level of endotoxin was markedly lowered after treatment (p<0.05).2. Compared with the normal control group or the therapy group after treatment, the serum level of IL-6 showed no significant difference in the therapy group before treatment (p>0.05).3. Cumulative scores of clinical symptoms after treatment decreased than that before treatment(p<0.05).4. The serum levels of K+ in therapy group before and after treatment were both in the normal range and there was no significant difference between the two groups (p>0.05).[Conclusions] Kidney-benefiting and Spleen-fortifying Pill can reduce the serum level of CRP and the plasma level of endotoxin, which proves that Kidney-benefiting and Spleen-fortifying Pill can improve the microinflammatory state in patients with uremia undergoing maintenance hemodialysis in the certain extent. In addition, Kidney-benefiting and Spleen-fortifying Pill is beneficial in reducing the clinical symptom score without increasing the serum level of K+.更多还原